Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Iterum Therapeutics

Iterum Therapeutics
2015 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
ITRM STOCK SYMBOL
$3.91 SHARE PRICE (As of Tuesday Closing)
Description

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • Block 2 Floor 3, Harcourt Centre
  • Harcourt Street
  • Dublin 2
  • Ireland

+353 (01) 000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Iterum Therapeutics’s full profile, request a free trial.

Iterum Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.80 - $9.30 $56.4M $3.88 -$6.33 12K 14.4M

Iterum Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 43,455 (22,627)
Revenue 530 869 508 0
EBITDA (95,925) (76,022) (29,174) (13,351)
Net Income (97,380) (77,056) (29,406) (13,464)
Total Assets 71,293 97,871 46,757 26,917
Total Debt 14,267 14,098 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Iterum Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Iterum Therapeutics‘s full profile, request access.

Request full access to PitchBook

Iterum Therapeutics Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Auspherix Venture Capital-Backed Stevenage, United Kingdom 00 0000 00000000000 0000
0000000 0000000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 00000000 00000
0000000 Formerly VC-backed Zurich, Switzerland 0 000.00 000000&0 000.00
000000 00000000000 Corporate Backed or Acquired Rockville, MD 00 000000000000
000 000000000 Venture Capital-Backed Bellshill, United Kingdom 0 000.00 0000000000 0 000.00
To view this company’s complete list of competitors, request access »

Iterum Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Iterum Therapeutics‘s full profile, request access.

Request full access to PitchBook

Iterum Therapeutics Executive Team (8)

Name Title Board
Seat
Contact
Info
Corey Fishman Chief Executive Officer & Board Member
Judith Matthews Chief Financial Officer & Chief Accounting Officer
Michael Dunne MD Chief Scientific Officer
John White Vice President, Business Development & Supply Chain
Tom Loughman Ph.D Vice President, CMC Head & Manufacturing

1 Former Executive

You’re viewing 5 of 8 executives. Get the full list »

Iterum Therapeutics Board Members (14)

Name Representing Role Since Contact
Info
Corey Fishman Iterum Therapeutics Chief Executive Officer & Board Member 000 0000
David Kelly Iterum Therapeutics Board Member 000 0000
James Healy MD Self Board Member 000 0000
Mark Chin Self Board Member 000 0000
Patrick Heron Self Board Member 000 0000

9 Former Board Members

You’re viewing 5 of 14 board members. Get the full list »